Avalyn Pharma (NASDAQ:AVLN) Reaches New 52-Week Low - Should You Sell?

Key Points

• Avalyn Pharma shares fell to a new 52-week low of $22.24 and last traded at $23.57, well below the 50-day moving average of $32.28.
• Analyst sentiment remains mixed: the consensus rating is “Moderate Buy” with a $60.00 target price, although Weiss Ratings and Wall Street Zen rated the stock “Sell.”
• Avalyn reported a quarterly loss of $0.98 per share, slightly better than estimates, while analysts expect a full-year loss of $3.86 per share; the company is developing inhaled therapies for pulmonary fibrosis.

Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report)'s stock price hit a new 52-week low during trading on Tuesday. The stock traded as low as $22.24 and last traded at $23.57, with a volume of 9,188 shares. The stock had previously closed at $23.33.

Analyst Upgrades and Downgrades

AVLN has been the subject of a number of recent research reports. Weiss Ratings started coverage on shares of Avalyn Pharma in a research note on Thursday, August 13th. They set a "sell (d+)" rating for the company. Morgan Stanley lifted their target price on Avalyn Pharma from $53.00 to $57.00 and gave the company an "overweight" rating in a research report on Thursday, August 13th. Raymond James Financial started coverage on Avalyn Pharma in a research report on Friday, October 2nd. They issued an "outperform" rating and a $60.00 target price on the stock. Finally, Wall Street Zen lowered Avalyn Pharma from a "hold" rating to a "sell" rating in a report on Sunday, September 20th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $60.00.

Avalyn Pharma Stock Performance

The company has a market capitalization of $1.07 billion and a P/E ratio of -1.06. The company has a debt-to-equity ratio of 0.04, a quick ratio of 33.12 and a current ratio of 33.12. The company's fifty day moving average is $32.28.

Avalyn Pharma (NASDAQ:AVLN - Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.03) by $0.05. On average, analysts expect that Avalyn Pharma Inc. will post -3.86 EPS for the current fiscal year.

Institutional Trading of Avalyn Pharma

A number of large investors have recently added to or reduced their stakes in the company. Montanova Capital LLC bought a new position in shares of Avalyn Pharma in the 2nd quarter valued at about $82,402,000. Braidwell LP acquired a new position in shares of Avalyn Pharma during the 2nd quarter worth about $26,382,000. State Street Corp acquired a new position in shares of Avalyn Pharma during the 2nd quarter worth about $10,501,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Avalyn Pharma in the 2nd quarter valued at about $1,321,000.

Avalyn Pharma Company Profile

Avalyn Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious fibrotic lung diseases. The company's primary focus is pulmonary fibrosis, a group of progressive conditions in which scar tissue builds up in the lungs and impairs breathing.

Avalyn's lead product candidate is AP01, an inhaled formulation of pirfenidone being developed for the treatment of idiopathic pulmonary fibrosis and other forms of pulmonary fibrosis. By delivering therapy directly to the lungs, Avalyn aims to provide a treatment option that may improve local drug exposure while potentially reducing some of the tolerability challenges associated with oral antifibrotic therapies.

The company's development programs are centered on advancing inhaled medicines through clinical testing and, if successful, regulatory review.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.